About this Journal Submit a Manuscript Table of Contents
ISRN Pharmaceutics
Volume 2012 (2012), Article ID 108164, 4 pages
http://dx.doi.org/10.5402/2012/108164
Research Article

Microemulsion Drug Delivery System: For Bioavailability Enhancement of Ampelopsin

1Department of Pharmaceutics, College of Pharmacy, IPS Academy, Rajendra Nagar, Indore 452012, India
2Department of Pharmaceutics, Sri Balaji College of Pharmacy, Jaipur 302012, India
3Formulation Research and Development, Dr. Reddy’s Laboratories Ltd., Hyderabad 500034, India

Received 31 March 2012; Accepted 26 April 2012

Academic Editors: K. Arya, P. P. Nekkar Rao, and R. Zelkó

Copyright © 2012 Shailendra Singh Solanki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Ampelopsin, one of the most common flavonoids, reported to possess numerous pharmacological activities and shows poor aqueous solubility. The purpose of this study was to enhance the dissolution rate and bioavailability of this drug by developing a novel delivery system that is microemulsion (ME) and to study the effect of microemulsion (ME) on the oral bioavailability of ampelopsin. Capmul MCM-based ME formulation with Cremophor EL as surfactant and Transcutol as cosurfactant was developed for oral delivery of ampelopsin. Optimised ME was evaluated for its transparency, viscosity, percentage assay and so forth. Solubilisation capacity of the ME system was also determined. The prepared ME was compared with the pure drug solution and commercially available tablet for in vitro drug release. The optimised ME formulation containing ampelopsin, Capmul MCM (5.5%), Cremophor EL (25%), Transcutol P (8.5%), and distilled water showed higher in vitro drug release, as compared to plain drug suspension and the suspension of commercially available tablet. These results demonstrate the potential use of ME for improving the bioavailability of poor water soluble compounds, such as ampelopsin.